Antiphospholipid antibodies as a potential factor of tumor progression

• Váldodahkkit: Z. D. Aslanova (Dahkki), J. Kh. Khizroeva (Dahkki), A. G. Solopova (Dahkki), V. O. Bitsadze (Dahkki), A. V. Vorobev (Dahkki), J.-C. Gris (Dahkki), I. Elalamy (Dahkki), N. A. Makatsariya (Dahkki), D. Yu. Zabolotnaya (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: IRBIS LLC, 2024-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Introduction. Current generally accepted clinical and laboratory criteria for antiphospholipid syndrome (APS) have been clearly determined, which include vascular thrombosis and pregnancy complications in patients with circulating antiphospholipid antibodies (aPLs). However, in the last several year...